(Q39325954)

English

Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Shingo Eikawa

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Kazuhiro Kakimi

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Midori Isobe

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Kiyotaka Kuzushima

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Immanuel Luescher

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yoshihiro Ohue

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Kazuhiro Ikeuchi

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Akiko Uenaka

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hiroyoshi Nishikawa

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Heiichiro Udono

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mikio Oka

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Eiichi Nakayama

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

11 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

132

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

345-354

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

NY-ESO-1: review of an immunogenic tumor antigen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Cancer/testis antigens, gametogenesis and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27682

21 January 2018

Identifiers

10.1002/IJC.27682

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39325954&oldid=1820211861"